Century Therapeutics
Philadelphia, PA · Founded 2019 · CIK 0001850119 · Biotech · Private
Allogeneic, iPSC-derived NK and T cell therapies for cancer and immune diseases
centurytx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $160M
- 1 Form D · Mar 2021
- 67 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 3 granted · 37 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $160,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3303 | Stramsen Biotech, Inc. | — | $5.0M |
| 3304 | Syncromune, Inc. | — | $56M |
| 3305 | TuHURA Biosciences, Inc. | — | $21M |
| 3306 | Century Therapeutics | — | $160M |
| 3307 | SilverCeuticals Inc. | — | $5.0M |
| 3308 | ORF Biologics, Inc. | — | $2.5M |
| 3309 | Blue Marlin Data Fund, LLC | — | $16M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Toshikazu BanDirector
- Cynthia ButittaDirector
- Douglas CarrExecutive Officer
- Eli CasdinDirector
- Juergen EckhardtDirector
- Osvaldo Flores, Ph.D.Director · Executive Officer
- Joseph JimenezDirector
- Carlo RizzutoDirector
Patents
- Cells Expressing Antigen- & Sequence-specific T-cell Receptors (tcrs) And Methods Of Making The Same Using Enforced Tcr Gene Rearrangementapplication
- Immunoeffector Cells Derived From Induced Pluripotent Stem Cells Genetically Engineered With Membrane Bound IL12 And Uses Thereofapplication
- Cells Engineered With An Hla-e And Hla-g Transgeneapplication
- Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereofgranted
- Genetically Engineered Cells Having ANTI-CD133 / Anti-egfr Chimeric Antigen Receptors, And Uses Thereofapplication
- Genetically Engineered Cells Having ANTI-CD19 / ANTI-CD22 Chimeric Antigen Receptors, And Uses Thereofapplication
- Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem Cellsapplication
- Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereofapplication
- Chimeric Antigen Receptor System With Adaptable Receptor Specificityapplication
- Chimeric Antigen Receptor System With Adaptable Receptor Specificitygranted
- Methods For Controlled Activation And/or Expansion Of Genetically Engineered Cells Using Polyethylene Glycol (peg) Receptorsapplication
- Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereofgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.